Pneumococcal vaccine and uses thereof

a new type of vaccine and pneumococcal technology, applied in the field of new pneumococcal vaccines, can solve the problems of insufficient information on disease burden, major public health problems of pneumococci, and inability to detect and treat pneumococci, so as to achieve safe and effective t-cell dependent carrier of saccharides and eliminate the toxic properties of diphtheria toxin

Inactive Publication Date: 2012-03-01
COLEY PHARM GRP INC
View PDF5 Cites 55 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0086]In a preferred embodiment, the capsular saccharide antigens of the invention are conjugated to CRM197 protein. The CRM197 protein is a nontoxic form of diphtheria toxin but is immunologically indistinguishable from the diphtheria toxin. CRM197 is produced by C. diphtheriae infected by the nontoxigenic phage β197tox- created by nitrosoguanidine mutagenesis of the toxigenic corynephage beta (Uchida, T. et al. 1971, Nature New Biology 233:8-11). The CRM197 protein has th...

Problems solved by technology

Pneumococcal diseases are a major public health problem all over the world.
Infections caused by pneumococci are a major cause of morbidity and mortality all over the world.
In spite of the importance of pneumococcal disease, there is a scarcity of information on disease burden, particularly from developing countries.
This is partly due to the inherent problem of obtaining an etiological diagnosis in cases of pneumonia.
However, based on available data, acute respiratory infections kill an estimated 2.6 million children under five years of age annually.
Pneumococcal resistance to essent...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pneumococcal vaccine and uses thereof
  • Pneumococcal vaccine and uses thereof
  • Pneumococcal vaccine and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 2

Immunogenicity and Safety of TLR9-Adjuvanted Pneumococcal Vaccines in HIV-Infected Adults. Results of the Randomized, Double-Blind, Placebo-Controlled Trial

[0303]The clinical trial described in example 1 was conducted.

[0304]The study was a placebo-controlled phase II trial randomizing persons with HIV to be vaccinated with double doses of PCV (pneumococcal conjugate vaccine) (Prevnar) ±1 mg CpG 7909 at 0 and 3 months and with one single dose of PPV (pneumococcal polysaccharide vaccine) ±1 mg CpG 7909 at 9 months. Immunogenicity and safety were evaluated at 0, 3, 4, 9, and 10 months. Primary endpoint was proportion of vaccine high-responders defined as 2-fold increase and IgG levels ≧1 μg / mL to at least 5 of 7 PCV serotypes (quantitative IgG by ELISA, Statens Serum Institute, Copenhagen, Denmark) at 9 months.

[0305]Results: As shown in table 1, 96 participants were included. In each group of 48 participants, 38 were on ART.

TABLE 1Baseline characteristics at time of inclusionPlacebo gr...

example 3

TLR9-Agonist Adjuvant Induces Cellular Memory in Response to Pneumococcal Conjugate Vaccine in HIV-Infected Adults

[0314]We examined how CPG 7909, affected the induction of cellular memory in response to pneumococcal conjugate vaccine.

[0315]Methods: Periferal blood mononuclear cells (PBMC) from 40 HIV-infected individuals from the double-blind, placebo-controlled phase Ib / IIa trial of Example 1 (20 subjects in each group) were collected at month 0 and 4 and were stored (frozen).

[0316]The Frozen PBMCs were thawed and tested for viability and transferred to 96-well flat-bottomed tissue culture plates. The cells were incubated overnight at 37° C., and stimulated the following day with purified pneumococcal polysaccharide (serotype (ST) 6B and 14). After 48 hours incubation, the supernatants were harvested and cytokine concentrations measured by Luminex. The relative response was calculated as the ratio between cytokine concentrations post- and pre-immunization, taking pre-existing immun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Forceaaaaaaaaaa
Forceaaaaaaaaaa
Login to view more

Abstract

The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.

Description

FIELD OF THE INVENTION[0001]The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.BACKGROUND OF THE INVENTION[0002]Pneumococcal diseases are a major public health problem all over the world. Infections caused by pneumococci are a major cause of morbidity and mortality all over the world. Pneumonia, febrile bacteraemia and meningitis are the most common manifestations of invasive pneumococcal disease, whereas bacterial spread within the respiratory tract may result in middle-ear infection, sinusitis or recurrent bronchitis. Compared with invasive disease, the non-invasive manifestations are usually less severe, but considerably more common.[0003]In spite of the importance of pneumococcal disease, there is a scarcity of information on disease burden, particularly from developing countries. This is partly due to th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/385A61P31/04A61P31/12A61P35/00A61P3/00A61P31/18A61P9/00A61P11/00A61P9/04A61P3/10A61P1/16A61P25/32A61P25/00A61P11/08A61P1/00A61P7/00A61P35/02A61P13/12A61P11/06A61K39/39A61K39/09
CPCA61K39/092A61K2039/6037A61K2039/55561A61K39/385A61P1/00A61P1/16A61P11/00A61P11/06A61P11/08A61P13/12A61P25/00A61P25/32A61P3/00A61P31/04A61P31/12A61P31/18A61P35/00A61P35/02A61P37/04A61P43/00A61P7/00A61P9/00A61P9/04A61P3/10A61K39/09A61K39/39A61K48/00
Inventor DAVIS, HEATHER LYNNKRIEG, ARTHUR MERTZLOHSE, NICOLAIOSTERGAARD, LARSSCHONHEYDER, HENRIK CARLSOGAARD, OLE SCHMELTZ
Owner COLEY PHARM GRP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap